– USA, MA – Combined Therapeutics Inc. (CTx), a biotechnology company developing the next generation of mRNA therapeutics to prevent and treat infectious diseases and cancer, today announced the appointments of Dr. Paul Wotton (Ph.D.), Dr. Bob Ruffolo (Ph.D.), and Kevin McLaughlin to its Board of Directors.
“The additions of Paul, Robert, and Kevin to our board bring together highly accomplished executives with extensive industry experience that is aligned with our development strategy. We are finalizing our financing round and putting in place the infrastructure to advance our mRNA vaccines and therapeutics into clinical development,” said Co-founder and CEO, Dr. Romain Micol.
About Dr. Paul Wotton
Dr. Paul Wotton is a serial entrepreneur and inventor with more than 30 years of experience in the biotech and pharma industries. He brings to Combined’s board a strong background in overall business leadership, product development, and transformational business transactions. He currently serves on the boards of Vericel, Cynata Therapeutics, and Kytopen, and is a co-founder and director of Avenge Bio. Recently, Dr. Wotton was CEO of Obsidian Therapeutics, where he led fundraising initiatives, built the management team, and directed the advancement of an engineered TIL therapy candidate for the treatment of melanoma into its first clinical trial. Before this, he was president and CEO of Ocata Therapeutics until its acquisition by Astellas Pharma.
He received his B.Pharm from University College London and his Ph.D. in pharmaceutical sciences from the University of Nottingham.
About Dr. Robert Ruffolo
Dr. Bob Ruffolo is the former president of research & development at Wyeth Pharmaceuticals and brings a wealth of experience in drug discovery and development. At Wyeth, he supervised an R&D organization of more than 7,000 scientists with an annual budget of more than $3 billion. Before this, he was SVP of biological sciences worldwide at SmithKline Beecham (now GSK). Dr. Ruffolo’s research groups have brought 37 new medicines to market. In addition, he has published more than 500 papers and edited 15 books. Dr. Ruffolo was awarded the prestigious Discoverer’s Award for the discovery of carvedilol (Coreg®) for the treatment of congestive heart failure, which changed the paradigm for the treatment of this devastating disease.
He received his B.S. in pharmacy from The Ohio State University and his Ph.D. in pharmacology from that same institution.
About Kevin F. McLaughlin
Kevin McLaughlin is a finance and management executive with more than 40 years of experience in the biopharma and high-tech industries. He was most recently SVP, CFO, and treasurer with Acceleron Pharma. During his 11-year tenure, he was a key member of management that helped to drive the company’s growth from a private research-focused business to a publicly traded commercial entity that Merck acquired for $11.5 billion. Mr. McLaughlin also serves as a director of Vericel Corporation and Decibel Therapeutics.
He earned a B.S. in accounting and physical distribution management from Northeastern University and an MBA from Babson College.
About Combined Therapeutics
Combined Therapeutics Inc. (CTx) is a privately held biotechnology company developing the next generation of high-value mRNA vaccines to protect everyone including vulnerable populations from global infectious diseases as well as to treat cancer. The company’s unique and proprietary mRNA platform with an increased safety profile, due to controlled biodistribution and high specificity, is built around Multi Organ Protective (MOPCTx) binding miRNA sequences combined with therapeutic mRNAs, allowing the targeting of therapeutic protein expression in specific tissues while reducing off-target effects to protect key vital organs such as the heart, liver, and kidneys. The company’s initial focus is on developing vaccines and vaccine adjuvants for infectious diseases and oncology indications with plans to initiate clinical development in 2024.
Combined Therapeutics is based in Boston and has international operations located in London and Paris.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.